Blocknomi
TLDR Roche stock jumps 2.60% as Phase 3 kidney drug results boost market momentum. Sefaxersen cuts proteinuria by 43.1% in a pivotal Phase 3 IgA nephropathy trial. Phase 3 data…
Related articles
-
ZachXBT Traces Over $20M in Illicit Flows Through FreedomXMR on Hyperliquid
BlockchainReporter Published 21.10.2026 03:54
-
Anthropic warns ‘AI worms’ may autonomously spread across devices like a virus
Cointelegraph Published 13.10.2026 13:55
-
CFTC Wants Clearer Rules for Leveraged Crypto Trading in Major US Regulatory Push
CryptoPotato Published 06.10.2026 22:11
-
Digital Euro Timeline: Lagarde Ties 2027 Pilot to Year-End Law
BlockchainReporter Published 17.10.2026 23:32
-
Vitalik Says Ethereum's ZK Speed Race Is Won. What It Means for ETH
BeInCrypto Published 15.10.2026 04:42
-
Startale Bond Puts a Yen Stablecoin to Work in Corporate Finance
Bitcoin.com Published 07.10.2026 01:30
-
BitTorrent Ushers in Next-Gen Web3 Infrastructure with Strategic Rebrand and Inaugural BTT Burn
CryptoSlate Published 18.10.2026 11:58
-
Levi Strauss & Co. (LEVI) Stock: Falls After Q3 Revenue Hits $1.6B and DTC Growth Disappoints
Blocknomi Published 07.10.2026 21:15